Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit

Abstract

Admission to the intensive care unit related to immune-related adverse event was associated with better outcome in cancer patients treated with immune checkpoint inhibitors. Our results support the admission for an intensive care unit trial for patients with suspected immune-related adverse events.